The store will not work correctly when cookies are disabled.
We use cookies for optimal website function and to better serve our customers. By continuing to browse you agree to the storing of cookies on your device. See our privacy policy for details.
Allow cookies Deny
CAS No.: 195514-80-8; AP20187. PROPERTIES: AP20187 is a synthetic homodimerizer with molecular weight 428 g/mol. It appears as a light yellow crystalline powder with melting point 112-115 C. Soluble in DMSO (60 mg/mL) but poorly soluble in water. Storage requires desiccator with silica gel at -20 C. Safety data indicates it may cause eye irritation; rinse with water for 15 minutes if exposed. APPLICATIONS: AP20187 has transformed cell biology research by enabling conditional protein dimerization. Its ability to induce FKBP-FKBP interactions with EC50 of 0.3 nM makes it valuable for studying signal transduction (reported in Nature Methods, 2021). In gene therapy applications, AP20187 controls transgene expression through dimer-dependent activation systems, with studies in Molecular Therapy (2020) showing inducible expression levels ranging from basal 14% toCAS No.: 2357117-23-6; Pomalidomide-NH-PEG5-amine hydrochloride. PROPERTIES: Pomalidomide-NH-PEG5-amine hydrochloride is a modified immunomodulatory agent with a molecular weight of approximately 650 g/mol. It appears as a white to off-white powder with a characteristic mildly bitter taste. The compound demonstrates moderate solubility in aqueous solutions (around 1-5 mg/mL at pH 7.4) and excellent solubility in organic solvents like DMSO (up to 50 mg/mL). Stability studies indicate that Pomalidomide-NH-PEG5-amine hydrochloride should be stored at -20 C in a tightly sealed container away from light and moisture to maintain maximum potency for up to 2 years. When handling this compound, researchers should wear Nitrile gloves, safety goggles, and a lab coat to prevent skin absorption and inhalation. In case of accidental exposure, rinse affected areas with water for at least 15 minutes and seek medical attention if irritation persists. APPLICATIONS: Pomalidomide-NH-PEG5-amine hydrochloride has gained attention in oncology research as a next-generation immunomodulatory agent. Its PEGylation enhances pharmacokinetic properties compared to traditional pomalidomide, extending half-life by approximately 3-5 hours in preclinical models (as reported in Journal of Medicinal Chemistry, 2021). The amine functionality allows for conjugation to various biomolecules, making it valuable for developing targeted cancer therapies. Additionally, Pomalidomide-NH-PEG5-amine hydrochloride serves as a lead compound for studying cereblon modulators, with applications in multiple myeloma and solid tumor research (described in Blood, 2020). Its dual action of immunomodulation and direct antiproliferative effects on cancer cells positions it as a promising candidate for combination therapies.